Xiaogang Li, PhD, is the Director of the Epigenetics Core at the Kansas Polycystic Kidney Disease (PKD) Research and Translational Core Center, supported by the National Institutes of Health of the United States of America (USA). He is Associate Professor of Internal Medicine at the University of Kansas Medical Center (KUMC), USA. He also holds academic appointments at the Departments of Biochemistry and Molecular Biology, Anatomy and Cell Biology, and Cancer Biology at KUMC. His research encompasses both basic science and translational aspects of PKD. In particular, he is widely regarded as one of the world’s foremost authorities on epigenetics and renal inflammation in PKD. Furthermore, he re-evaluates the roles of apoptosis in autosomal dominant PKD, contributing to a better understanding of the mechanisms of this disease. He has published extensively in the field including publications in Nature Cell Biology, Nature Medicine, and Journal of Clinical Investigation. His studies are leading to the use of promising new therapeutic drugs in PKD treatment.